News & Events zu Quanterix Corp (QTRX)QTRXQuanterix Corp

Quanterix and Innovita Obtain Regulatory Approvals in China

Quanterix and Innovita Biological Technology announced regulatory approvals that advance access to the Quanterix SIMOA technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix's ultra-sensitive biomarker detection technology with Innovita's diagnostics development, regulatory and commercialization capabilities in China. Innovita has now received National Medical Products Administration approval for the Quanterix HD-X and SR-X instruments, as well as testing kits for four biomarkers relevant to neurological disease: p-Tau 217, GFAP, p-Tau 181 and NfL. Together, these approvals establish a broader SIMOA-powered neurology biomarker portfolio in China and represent an important step toward expanding access to blood-based biomarker testing as the Alzheimer's disease diagnostic and treatment landscape continues to evolve. The four biomarkers provide complementary insights into Alzheimer's disease pathology, neurodegeneration and neuroinflammation, supporting applications across the diagnostic continuum, from early screening to disease monitoring and prognostic assessment. As clinical practice increasingly shifts toward earlier identification and evaluation of Alzheimer's disease, highly sensitive blood-based testing becomes increasingly important. Biomarkers such as p-Tau 217 can be present at very low concentrations, creating sensitivity challenges for conventional immunoassay technologies. SIMOA ultra-sensitive analytical capabilities help address these challenges, supporting more informed clinical decision-making across the continuum of care.

Quanterix Achieves Significant Progress in Spatial Biology

Quanterix Corporation reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-first approach to revealing more from every tissue section. It is supported by the end-to-end capabilities spatial biologists need to advance beyond discovery: world-class spatial instrumentation, assay design and reagent formulation expertise, quality systems, and manufacturing scale to support measurements that meet the requirements of translational and clinical applications. Three programs previewed at AACR have since progressed, one now shipped and two confirmed for delivery in Q4 2026, underscoring the pace at which Quanterix is executing against this roadmap.

Quanterix Appoints Dr. Yuri Fesko as Chief Medical Officer

Quanterix Corporation (QTRX) announced that Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix's innovative technologies and applications. Dr. Fesko most recently served as Chief Medical Officer at Quest Diagnostics (DGX).